Tirzepatide often shows greater efficacy than semaglutide
Similarly, IM injections offer an effective alternative, though they are slightly slower than IV therapy in absorption
Last reviewed: 18 Jun 2026 Sources Wegovy tablet, emc [accessed 18 June 2026] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet [accessed 10 June 2026] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, The New England Journal of Medicine [accessed 10 June 2026] Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen, emc [accessed 10 June 2026] Wegovy 1.5 mg tablets SmPC/PIL, emc [accessed 18 June 2026] Related weight loss treatments Further reading on Wegovy pill Trusted by thousands Your health guided by experts Our doctors are regulated by the CQC and GPhC, the same bodies overseeing NHS care.

An in vitro cell experiment showed that the 2-AR agonist UK14,304 can increase cAMP levels in the cholangiocarcinoma cell line Mz-ChA-1, inhibit cell proliferation and suppress EGF-induced MAPK pathway activity by acutely upregulating Raf-1 and continuously activating B-Raf
Convenient Liquid Form No need for mixing or capsulesjust take a serving as part of your daily routine